Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 23;20:15347354211002647. doi: 10.1177/15347354211002647

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 2. — GT treatment on lymphocytes and NK cells of elderly AML-MRC patients. (A-B) Frequencies of PB CD8⁺ T and B cells. (C) Frequencies of PB granzyme B⁺/perforin⁺ CD8⁺ T cells. (D-E) Frequencies of BM and PB granzyme B⁺ NK cells. (F) Representative gating strategy of Treg cells (double positive CD25⁺/FOXP3⁺⁺ population selected as the percentage of CD4⁺ cells) by flow cytometry. (G-H) Frequencies of BM and PB Treg cells. (I) Frequencies of PB CXCR4⁺ Treg cells. BM and PB samples of 10 AML-MRC patients were analyzed before and after 30 days by flow cytometry. Wilcoxon test.

Abbreviations: AML-MRC, acute myeloid leukemia with myelodysplasia-related changes; BM, bone marrow; GT, green tea; NK, natural killer; PB, peripheral blood; Treg, regulatory T cells.